The future is today: emerging drugs for the treatment of erectile dysfunction

Bibliography

• NIH Consensus Conference. Impotence. NIH consensus development panel on impotence. JAMA 1993;270(1):83-90
   PubMedGoogle Scholar
• Uckert S, Mayer ME, Stief CG, Jonas U. The future of the oral pharmacotherapy of male erectile dysfunction: things to come. Expert Opin Emerg Drugs 2007;12(2):219-28
   PubMed Web of Science ®Google Scholar
• Derogatis LR, Burnett AL. The epidemiology of sexual dysfunctions. J Sex Med 2008;5(2):289-300
   PubMed Web of Science ®Google Scholar
• Saigal CS, Wessells H, Pace J, Urologic diseases in America Project. Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch Intern Med 2006;166(2):207-12
   PubMed Web of Science ®Google Scholar
• Albersen M, Shindel AW, Lue TF. Sexual dysfunction in the older man. Rev Clin Gerontol 2009;19:237-48
   Google Scholar
• Martinez-Pineiro L, Trigo-Rocha F, Hsu GL, Cyclic guanosine monophosphate mediates penile erection in the rat. Eur Urol 1993;24(4):492-9
   PubMed Web of Science ®Google Scholar
• Trigo-Rocha F, Aronson WJ, Hohenfellner M, Nitric oxide and cGMP: mediators of pelvic nerve-stimulated erection in dogs. Am J Physiol 1993;264(2 Pt 2):H419-22
   PubMedGoogle Scholar
• Trigo-Rocha F, Hsu GL, Donatucci CF, Lue TF. The role of cyclic adenosine monophosphate, cyclic guanosine monophosphate, endothelium and nonadrenergic, noncholinergic neurotransmission in canine penile erection. J Urol 1993;149(4):872-7
   PubMed Web of Science ®Google Scholar
• Boolell M, Allen MJ, Ballard SA, Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996;8(2):47-52
   PubMedGoogle Scholar
• Hatzimouratidis K, Hatzichristou DG. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? Drugs 2005;65(12):1621-50
   PubMed Web of Science ®Google Scholar
• Eardley I, Donatucci C, Corbin J, Pharmacotherapy for erectile dysfunction. J Sex Med 2010;7(1 Pt 2):524-40
   PubMed Web of Science ®Google Scholar
• Hackett G, Kell P, Ralph D, British society for sexual medicine guidelines on the management of erectile dysfunction. J Sex Med 2008;5(8):1841-65
   PubMed Web of Science ®Google Scholar
• Hatzimouratidis K, Amar E, Eardley I, Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010. [Epub ahead of print]
   Web of Science ®Google Scholar
• Giuliano F, Jackson G, Montorsi F, Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int J Clin Pract 2010;64(2):240-55
   PubMed Web of Science ®Google Scholar
• Hatzimouratidis K, Hatzichristou D. Phosphodiesterase type 5 inhibitors: the day after. Eur Urol 2007;51(1):75-88, discussion 89
   PubMed Web of Science ®Google Scholar
• Bella AJ, Deyoung LX, Al-Numi M, Brock GB. Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications. Eur Urol 2007;52(4):990-1005
   PubMed Web of Science ®Google Scholar
• Shindel AW. 2009 Update on phosphodiesterase type 5 inhibitor therapy part 1: recent studies on routine dosing for penile rehabilitation, lower urinary tract symptoms, and other indications (CME). J Sex Med 2009;6(7):1794-808, quiz 1793, 1809-10
   PubMed Web of Science ®Google Scholar
• Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004;172(2):658-63
   PubMed Web of Science ®Google Scholar
• Cellek S, Rees RW, Kalsi J. A rho-kinase inhibitor, soluble guanylate cyclase activator and nitric oxide-releasing PDE5 inhibitor: novel approaches to erectile dysfunction. Expert Opin Investig Drugs 2002;11(11):1563-73
   PubMed Web of Science ®Google Scholar
• Shindel AW. 2009 Update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class. J Sex Med 2009;6(9):2352-64, quiz 2365-6
   PubMed Web of Science ®Google Scholar
• Bella AJ, Brant WO, Lue TF, Brock GB. Non-arteritic anterior ischemic optic neuropathy (NAION) and phosphodiesterase type-5 inhibitors. Can J Urol 2006;13(5):3233-8
   PubMedGoogle Scholar
• Heaton JP, Altwein JE. The role of apomorphine SL in the treatment of male erectile dysfunction. BJU Int 2001;88(Suppl 3):36-8
   PubMed Web of Science ®Google Scholar
• Heaton JP. Central neuropharmacological agents and mechanisms in erectile dysfunction: the role of dopamine. Neurosci Biobehav Rev 2000;24(5):561-9
   PubMed Web of Science ®Google Scholar
• Riley A, Main M, Morgan F. Inhalation device allows novel administration of apomorphine in men with erectile dysfunction-efficacy and safety findings. J Sex Med 2009. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Pharmaprojects – Copyrights to citeline drug intelligence (an Informa Business)
   Google Scholar
• Alexandre B, Lemaire A, Desvaux P, Amar E. Intracavernous injections of prostaglandin E1 for erectile dysfunction: patient satisfaction and quality of sex life on long-term treatment. J Sex Med 2007;4(2):426-31
   PubMed Web of Science ®Google Scholar
• Hellstrom WJ. Clinical applications of centrally acting agents in male sexual dysfunction. Int J Impot Res 2008;20(Suppl 1):S17-23
   PubMedGoogle Scholar
• Brioni JD, Moreland RB, Cowart M, Activation of dopamine D4 receptors by ABT-724 induces penile erection in rats. Proc Natl Acad Sci USA 2004 101(17):6758-63
   PubMed Web of Science ®Google Scholar
• Baskerville TA, Douglas AJ. Interactions between dopamine and oxytocin in the control of sexual behaviour. Prog Brain Res 2008;170:277-90
   PubMed Web of Science ®Google Scholar
• Lue TF. Erectile dysfunction. N Engl J Med 2000;342(24):1802-13
   PubMed Web of Science ®Google Scholar
• Albersen M, Joniau S, Claes H, Van Poppel H. Preclinical evidence for the benefits of penile rehabilitation therapy following nerve-sparing radical prostatectomy. Adv Urol 2008;2008:594868
   Google Scholar
• Lin CS, Xin ZC, Wang Z, Molecular yin and yang of erectile function and dysfunction. Asian J Androl 2008;10(3):433-40
   PubMed Web of Science ®Google Scholar
• Prieto D. Physiological regulation of penile arteries and veins. Int J Impot Res 2008;20(1):17-29
   PubMed Web of Science ®Google Scholar
• Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides 2006;27(4):921-30
   PubMed Web of Science ®Google Scholar
• Hedlund P. Centrally acting drugs for erectile dysfunction: do they have a future? Curr Sex Health Rep 2007;4:71-6
   Google Scholar
• Perelman MA. Clinical application of CNS-acting agents in FSD. J Sex Med 2007;4(Suppl 4):280-90
   PubMed Web of Science ®Google Scholar
• Bivalacqua TJ, Champion HC, Usta MF, RhoA/Rho-kinase suppresses endothelial nitric oxide synthase in the penis: a mechanism for diabetes-associated erectile dysfunction. Proc Natl Acad Sci USA 2004;101(24):9121-6
   PubMed Web of Science ®Google Scholar
• Gratzke C, Angulo J, Chitaley K, Anatomy, physiology, and pathophysiology of erectile dysfunction. J Sex Med 2010;7(1 Pt 2):445-75
   PubMed Web of Science ®Google Scholar
• Chitaley K, Wingard CJ, Clinton WR, Antagonism of rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway. Nat Med 2001;7(1):119-22
   PubMed Web of Science ®Google Scholar
• Chitaley K, Webb RC, Mills TM. Rho-kinase as a potential target for the treatment of erectile dysfunction. Drug News Perspect 2001;14(10):601-6
   PubMed Web of Science ®Google Scholar
• Mills TM, Lewis RW, Wingard CJ, Inhibition of tonic contraction--a novel way to approach erectile dysfunction. J Androl 2002;23(5):S5-9
   PubMedGoogle Scholar
• Christ GJ, Wang HZ, Venkateswarlu K, Ion channels and gap junctions: their role in erectile physiology, dysfunction, and future therapy. Mol Urol 1999;3(2):61-73
   PubMedGoogle Scholar
• Christ GJ, Andersson KE, Williams K, Smooth-muscle-specific gene transfer with the human maxi-K channel improves erectile function and enhances sexual behavior in atherosclerotic cynomolgus monkeys. Eur Urol 2008. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Spektor M, Rodriguez R, Rosenbaum RS, Potassium channels and human corporeal smooth muscle cell tone: further evidence of the physiological relevance of the maxi-K channel subtype to the regulation of human corporeal smooth muscle tone in vitro. J Urol 2002;167(6):2628-35
   PubMed Web of Science ®Google Scholar
• Chan JS, Kim DJ, Ahn CH, Clavulanic acid stimulates sexual behaviour in male rats. Eur J Pharmacol 2009;609(1-3):69-73
   PubMed Web of Science ®Google Scholar
• Patel MV, Kolasa T, Mortell K, Discovery of 3-methyl-N-(1-oxy-3′,4′,5′,6′-tetrahydro-2′H-[2,4′-bipyridine]-1′-ylmethyl)benzam ide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. J Med Chem 2006;49(25):7450-65
   PubMed Web of Science ®Google Scholar
• King SH, Mayorov AV, Balse-Srinivasan P, Melanocortin receptors, melanotropic peptides and penile erection. Curr Top Med Chem 2007;7(11):1098-106
   PubMedGoogle Scholar
• Wessells H, Blevins JE, Vanderah TW. Melanocortinergic control of penile erection. Peptides 2005;26(10):1972-7
   PubMed Web of Science ®Google Scholar
• Wessells H, Hruby VJ, Hackett J, MT-II induces penile erection via brain and spinal mechanisms. Ann NY Acad Sci 2003;994:90-5
   PubMed Web of Science ®Google Scholar
• Wessells H, Fuciarelli K, Hansen J, Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol 1998;160(2):389-93
   PubMed Web of Science ®Google Scholar
• Martin WJ, MacIntyre DE. Melanocortin receptors and erectile function. Eur Urol 2004;45(6):706-13
   PubMed Web of Science ®Google Scholar
• Kaminetsky J, Zinner N, Gittleman M, Phase IIb study of bremelanotide in the treatment of ED in non-diabetic males. Proceedings Of The American Urology Association Annual Meeting; 19 – 24 May 2007; Anaheim, USA
   Google Scholar
• Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. J Urol 2008;179(3):1066-71
   PubMed Web of Science ®Google Scholar
• Eros D, Szantai-Kis C, Kiss R, Structure -activity relationships of PDE5 inhibitors. Curr Med Chem 2008;15(16):1570-85
   PubMed Web of Science ®Google Scholar
• Kim BH, Lim HS, Chung JY, Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young korean subjects. Br J Clin Pharmacol 2008;65(6):848-54
   PubMed Web of Science ®Google Scholar
• Paick JS, Ahn TY, Choi HK, Efficacy and safety of mirodenafil, a new oral phosphodiesterase type 5 inhibitor, for treatment of erectile dysfunction. J Sex Med 2008;5(11):2672-80
   PubMed Web of Science ®Google Scholar
• Kim BH, Yi S, Kim J, Influence of alcohol on the hemodynamic effects and pharmacokinetic properties of mirodenafil: a single-dose, randomized-sequence, open-label, crossover study in healthy male volunteers in korea. Clin Ther 2009;31(6):1234-43
   PubMed Web of Science ®Google Scholar
• Glina S, Fonseca GN, Bertero EB, Damiao R, Rocha LC, Jardim CRF, Efficacy and tolerability of lodenafil carbonate for oral therapy in erectile dysfunction: a phase II clinical trial. J Sex Med 2009;6(2):553-7
   PubMed Web of Science ®Google Scholar
• Glina S, Fonseca GN, Bertero EB, Efficacy and tolerability of lodenafil carbonate for oral therapy of erectile dysfunction: a phase III clinical trial. J Sex Med 2010; In Press
   Web of Science ®Google Scholar
• Rahimi R, Ghiasi S, Azimi H, A review of the herbal phosphodiesterase inhibitors; future perspective of new drugs. Cytokine 2010;49(2):123-9
   PubMed Web of Science ®Google Scholar
• Ning H, Xin ZC, Lin G, Effects of icariin on phosphodiesterase-5 activity in vitro and cyclic guanosine monophosphate level in cavernous smooth muscle cells. Urology 2006;68(6):1350-4
   PubMed Web of Science ®Google Scholar
• Xin ZC, Kim EK, Lin CS, Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl 2003;5(1):15-8
   PubMed Web of Science ®Google Scholar
• Liu WJ, Xin ZC, Xin H, Effects of icariin on erectile function and expression of nitric oxide synthase isoforms in castrated rats. Asian J Androl 2005;7(4):381-8
   PubMed Web of Science ®Google Scholar
• Shindel AW, Xin ZC, Lin G, Erectogenic and neurotrophic effects of icariin, a purified extract of horny goat weed (Epimedium spp.) in vitro and in vivo. J Sex Med 2010. [Epub ahead of print]
   Web of Science ®Google Scholar
• Qinna N, Taha H, Matalka KZ, Badwan AA. A new herbal combination, etana, for enhancing erectile function: an efficacy and safety study in animals. Int J Impot Res 2009;21(5):315-20
   PubMed Web of Science ®Google Scholar
• Brioni JD, Nakane M, Hsieh GC, Activators of soluble guanylate cyclase for the treatment of male erectile dysfunction. Int J Impot Res 2002;14(1):8-14
   PubMed Web of Science ®Google Scholar
• Ko FN, Wu CC, Kuo SC, YC-1, a novel activator of platelet guanylate cyclase. Blood 1994;84(12):4226-33
   PubMed Web of Science ®Google Scholar
• Mizusawa H, Hedlund P, Brioni JD, Nitric oxide independent activation of guanylate cyclase by YC-1 causes erectile responses in the rat. J Urol 2002;167(5):2276-81
   PubMed Web of Science ®Google Scholar
• Hsieh GC, O'Neill AB, Moreland RB, YC-1 potentiates the nitric oxide/cyclic GMP pathway in corpus cavernosum and facilitates penile erection in rats. Eur J Pharmacol 2003;458(1-2):183-9
   PubMed Web of Science ®Google Scholar
• Nakane M, Hsieh G, Miller LN, Activation of soluble guanylate cyclase causes relaxation of corpus cavernosum tissue: synergism of nitric oxide and YC-1. Int J Impot Res 2002;14(2):121-7
   PubMed Web of Science ®Google Scholar
• Kalsi JS, Kell PD, Cellek S, Ralph DJ. NCX-911, a novel nitric oxide-releasing PDE5 inhibitor relaxes rabbit corpus cavernosum in the absence of endogenous nitric oxide. Int J Impot Res 2004;16(2):195-200
   PubMed Web of Science ®Google Scholar
• Kalsi JS, Rees RW, Hobbs AJ, BAY41-2272, a novel nitric oxide independent soluble guanylate cyclase activator, relaxes human and rabbit corpus cavernosum in vitro. J Urol 2003;169(2):761-6
   PubMed Web of Science ®Google Scholar
• Miller LN, Nakane M, Hsieh GC, A-350619: a novel activator of soluble guanylyl cyclase. Life Sci 2003;72(9):1015-25
   PubMed Web of Science ®Google Scholar
• Gur S, Kadowitz PJ, Hellstrom WJ. Exploring the potential of no-independent stimulators and activators of soluble guanylate cyclase for the medical treatment of erectile dysfunction. Curr Pharm Des 2010. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Kalsi JS, Ralph DJ, Madge DJ, A comparative study of sildenafil, NCX-911 and BAY41-2272 on the anococcygeus muscle of diabetic rats. Int J Impot Res 2004;16(6):479-85
   PubMed Web of Science ®Google Scholar
• Schmidt HH, Schmidt PM, Stasch JP. NO- and haem-independent soluble guanylate cyclase activators. Handb Exp Pharmacol 2009;191:309-39
   PubMedGoogle Scholar
• Kun A, Kiraly I, Pataricza J, C-type natriuretic peptide hyperpolarizes and relaxes human penile resistance arteries. J Sex Med 2008;5(5):1114-25
   PubMed Web of Science ®Google Scholar
• Sousa CM, Havt A, Santos CF, The relaxation induced by uroguanylin and the expression of natriuretic peptide receptors in human corpora cavernosa. J Sex Med 2010. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Riffaud JP, Bernarbe J, Giuliano F, Pharmacological profile of sildenafil nitrate (NCX 911) in various models of penile erection. Inflamm Res 2001;50(Suppl 3):S84
   PubMedGoogle Scholar
• Kalsi JS, Ralph DJ, Thomas P, A nitric oxide-releasing PDE5 inhibitor relaxes human corpus cavernosum in the absence of endogenous nitric oxide. J Sex Med 2005;2(1):53-7
   PubMed Web of Science ®Google Scholar
• Seidler M, Uckert S, Waldkirch E, In vitro effects of a novel class of nitric oxide (NO) donating compounds on isolated human erectile tissue. Eur Urol 2002;42(5):523-8
   PubMed Web of Science ®Google Scholar
• Chitaley K, Webb RC, Mills TM. The ups and downs of rho-kinase and penile erection: upstream regulators and downstream substrates of rho-kinase and their potential role in the erectile response. Int J Impot Res 2003;15(2):105-9
   PubMed Web of Science ®Google Scholar
• Chang S, Hypolite JA, Changolkar A, Increased contractility of diabetic rabbit corpora smooth muscle in response to endothelin is mediated via rho-kinase beta. Int J Impot Res 2003;15(1):53-62
   PubMed Web of Science ®Google Scholar
• Park K, Kim SW, Rhu KS, Paick JS. Chronic administration of an oral rho kinase inhibitor prevents the development of vasculogenic erectile dysfunction in a rat model. J Sex Med 2006;3(6):996-1003
   PubMed Web of Science ®Google Scholar
• Buyukafsar K, Un I. Effects of the rho-kinase inhibitors, Y-27632 and fasudil, on the corpus cavernosum from diabetic mice. Eur J Pharmacol 2003;472(3):235-8
   PubMed Web of Science ®Google Scholar
• Lohn M, Plettenburg O, Ivashchenko Y, Pharmacological characterization of SAR407899, a novel rho-kinase inhibitor. Hypertension 2009;54(3):676-83
   PubMed Web of Science ®Google Scholar
• Christ GJ. K channels as molecular targets for the treatment of erectile dysfunction. J Androl 2002;23(5):S10-9
   PubMedGoogle Scholar
• Lee SW. Physiological roles and properties of potassium channels in corporal smooth muscle. Drugs Today (Barc) 2000;36(2-3):147-54
   PubMed Web of Science ®Google Scholar
• Werner ME, Zvara P, Meredith AL, Erectile dysfunction in mice lacking the large-conductance calcium-activated potassium (BK) channel. J Physiol 2005;567(Pt 2):545-56
   PubMed Web of Science ®Google Scholar
• Boy KM, Guernon JM, Sit SY, 3-thio-quinolinone maxi-K openers for the treatment of erectile dysfunction. Bioorg Med Chem Lett 2004;14(20):5089-93
   PubMed Web of Science ®Google Scholar
• Lifestyle drugs market outlook. key indications, epidemiology, and emergent drugs. new healthcare report – published december 2007. Sample information available from: www.globalbusinessinsights.com. [Last accessed 10 February 2010]
   Google Scholar
• Erectile dysfunction market assessment and analysis 2007 – 2022. Abstract. Available from: www.marketresearch.com. [Last accessed 10 February 2010]
   Google Scholar